A biologist at the French-Austrian biotech company Valneva works on an inactivated whole-virus vaccine against the coronavirus in Vienna, Austria, in December 2021. Reuters
A biologist at the French-Austrian biotech company Valneva works on an inactivated whole-virus vaccine against the coronavirus in Vienna, Austria, in December 2021. Reuters